Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

(2015) Kristian Reich et al.   EXPERIMENTAL DERMATOLOGY

Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion

(2015) Christian Dragatin et al.   EXPERIMENTAL DERMATOLOGY

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

(2015) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin 17A: Toward a new understanding of psoriasis pathogenesis

(2014) Charles W. Lynde et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

(2014) C. Paul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and early clinical data on IL-17 blockade in psoriasis

(2013) Steven M Nwe et al.   Expert Review of Clinical Immunology

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study

(2012) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional Specialization of Interleukin-17 Family Members

(2011) Yoichiro Iwakura et al.   IMMUNITY

Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients

(2011) T. Gambichler et al.   REGULATORY PEPTIDES

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis

(2009) Shinji Kagami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin

(2009) Patrick A. M. Jansen et al.   PLoS One

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Differential mRNA Expression of Antimicrobial Peptides and Proteins in Atopic Dermatitis as Compared to Psoriasis Vulgaris and Healthy Skin

(2008) Thilo Gambichler et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis

(2008) Andrew Blauvelt   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY